FOR IMMEDIATE RELEASE MARCH 8, 2012
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) will be presenting at the ROTH Capital Partners Growth Stock Conference in Laguna Niguel, CA, on Tuesday, March 13, 2012, at 3:30 p.m. Pacific Time. Bob Butchofsky, QLT's President and Chief Executive Officer, will be discussing the Company's two primary development programs: (i) a synthetic retinoid, QLT091001, for the treatment of Leber Congenital Amaurosis and Retinitis Pigmentosa; and (ii) the Company's Punctal Plug Delivery System primarily for the treatment of glaucoma.
The live audio webcast of QLT’s presentation can be accessed through the Company’s web site at www.qltinc.com.
QLT is an biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases, developing our proprietary punctal plug delivery system, as well as U.S. marketing of the commercial product Visudyne® for the treatment of wet age-related macular degeneration.
QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com.
office: 604-707-7000 or 1-877-764-3131
Visudyne® is a registered trademark of Novartis AG.